Journal Mobile Options
Table of Contents
Vol. 72, Suppl. 1, 2007
Issue release date: December 2007
Oncology 2007;72:132–138
(DOI:10.1159/000111719)

Long-Term Interferon Maintenance Therapy Improves Survival in Patients with HCV-Related Hepatocellular Carcinoma after Curative Radiofrequency Ablation

A Matched Case-Control Study

Kudo M. · Sakaguchi Y. · Chung H. · Hatanaka K. · Hagiwara S. · Ishikawa E. · Takahashi S. · Kitai S. · Inoue T. · Minami Y. · Ueshima K.
Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: To assess whether low-dose, long-term maintenance interferon (IFN) therapy inhibits recurrence after complete ablation of hepatocellular carcinoma (HCC) and improves patient survival. Methods and Patients: From June 1999 through May 2006, a total of 127 HCC cases that met the requirements of both tumor diameter 3 cm or less, and number of tumors three or fewer, were curatively treated by radiofrequency ablation therapy (RFA). Among them, 43 patients received three million IU of IFN-α2b twice per week or pegylated IFN-α2a 90 µg once per week or once per 2 weeks without discontinuation (IFN maintenance group). The remaining 84 patients, whose sex, age, and platelet counts were randomly matched to those of the IFN maintenance group, did not receive IFN treatment (control group). Results: Cumulative first, second, and third recurrence rates were significantly reduced in the IFN maintenance group compared with the control group by Kaplan-Meier estimate. The 5-year survival rate was 66% for the control group and 83% for the IFN maintenance group (p = 0.004). Multivariate analysis using the Cox proportional hazards model identified IFN maintenance therapy as an independent risk factor for survival, and the risk ratio was 0.21 (95% CI: 0.05–0.73). In conclusion, low-dose, long-term maintenance IFN therapy after curative RFA therapy of HCC significantly inhibits recurrence, and consequently improves patient survival.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. El-Serag HB: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001;5:87–107.
  2. El-Serag HB: Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002;35:S72–S78.
  3. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB: Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127:1372–1380.
  4. Bosch FX, Ribes J, Cleries R, Diaz M: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9:191–211.
  5. Kiyosawa K, Umemura T, Ichijyo T, Matsumoto A, Yoshizawa K, Gad A, et al: Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004;127:S17–S26.
  6. National Institutes of Health: National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C. Hepatology 2002;36(suppl 1):S3–S20.
  7. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S: Effect of treatment with peginterferon or interferon alpha-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75–85.
  8. Hisaka T, Yano H, Ogasawara S, Momosaki S, Nishida N, Takemoto Y, Kojiro S, Takafuchi Y, Kojiro M: Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo. J Hepatol 2004;41:782–789.
  9. Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T: Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005;48:64–70.
  10. Suou T, Mitsuda A, Koda M, Matsuda H, Maruyama S, Tanaka H, et al: Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res 2001;20:301–311.
  11. Kubo S, Kinoshita H, Hirohashi K, Tanaka H, Tsukamoto T, Hamba H, et al: Patterns of and risk factors for recurrence after liver resection for well-differentiated hepatocellular carcinoma: a special reference to multicentric carcinogenesis after operation. Hepatogastroenterology 1999;46:3212–3215.
  12. Benvegnu L, Alberti A: Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis. Antiviral Res 2001;52:199–207.
  13. Kudo M: Local ablation therapy for hepatocellular carcinoma: current status and future perspective. J Gastroenterol 2004;39:205–214.
  14. Toyoda H, Kumada T, Honda T, Hayashi K, Katano Y, Nakano I, et al: Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C. J Gastroenterol Hepatol 2001;16:1131–1137.
  15. Enokimura N, Shiraki K, Kawakita T, Saitou Y, Inoue H, Okano H, et al: Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C. Anticancer Res 2003;23:593–596.
  16. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299–306.
  17. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma: a randomized, controlled trial. Ann Intern Med 2001;134:963–967.
  18. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002;89:418–422.
  19. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamto T, Shuto T, et al: Influence of previous interferon therapy on recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Jpn J Cancer Res 2001;92:59–66.
  20. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228–232.
  21. Hisaka T, Yano H, Ogasawara S, Momosaki S, Nishida N, Takemoto Y, et al: Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo. J Hepatol 2004;41:782–789.
  22. Von Marschall Z, Scholz A, Cramer T, Scafer G, Schirner M, Oberg K, et al: Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003;95:437–448.
  23. Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, Liu YK, et al: Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 2003;7:587–594.
  24. Murphy D, Detjen KM, Welzel M, Wiedenmann B, Rosewicz S: Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 2001;33:346–356.
  25. Yano H, Iemura A, Haramaki, Ogasawara S, Takayama A, Akiba J, et al: Interferon alpha receptor expression and growth inhibition by interferon alpha in human liver cancer cell lines. Hepatology 1999;29:1708–1717.
  26. Mallat DB, El-Serag HB: Interferon for postresection recurrence of hepatocellular carcinoma. Am J Gastroenterol 2002;97:3200–3202.

    External Resources

  27. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, et al: Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004;100:376–382.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50